GlassScriptPhysician profile
Versan S Johnson
NPI 1447549985
$975.65
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $376 · 2021: $210 · 2022: $29.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.42 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $152.95 | 2019-2021 | |
| Pfizer INC. | $116.09 | 2019-2021 | |
| Vertos Medical, INC. | $68.23 | 2021 | |
| Medtronic USA, INC. | $64.48 | 2019-2020 | |
| West Therapeutics Development, LLC | $48.39 | 2019-2021 | |
| Allergan, INC. | $43.10 | 2019-2020 | |
| Boston Scientific Corporation | $42.34 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $34.65 | 2019-2021 | |
| Si-Bone, INC. | $34.60 | 2019 | |
| Redhill Biopharma INC. | $34.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $28.63 | 2019 | |
| Abbott Laboratories | $24.13 | 2019 | |
| Zyla Life Sciences, INC. | $23.39 | 2019 | |
| Hikma Pharmaceuticals USA | $17.74 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $16.39 | 2020 | |
| Mdd US Operations, LLC | $15.46 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.37 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Versan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.